2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
April 14th, 2025
Version: 1
Baylor University
cancer biology
biorxiv

Ophiobolin A selectively alters mitochondria, metabolism and redox biology in breast cancer and mammary epithelial cells which have undergone epithelial to mesenchymal transition

Parker, H.Open in Google Scholar•Tao, Y.Open in Google Scholar•Tobin, J.Open in Google Scholar•Haberman, K. L.Open in Google Scholar•Davis, S.Open in Google Scholar•York, E.Open in Google Scholar•Martinez, A.Open in Google Scholar•Matsumoto, N.Open in Google Scholar•Aroujo, J.Open in Google Scholar•Park, J.Open in Google Scholaret al.

Breast cancer progression is facilitated by the epithelial to mesenchymal transition (EMT), generating cancer cells with enhanced metastatic capacity and resistance to chemotherapeutics. EMT is known to impart changes in metabolic pathways and mitochondrial function. Here, we show a natural product possesses EMT-specific cytotoxic activity via alterations in metabolic and mitochondrial functions. The fungus-derived sesterterpenoid, ophiobolin A (OpA), possesses nanomolar cytotoxic activity and a high therapeutic index, although its target and mechanism of action remain unknown. Here, we utilized a model of mammary epithelial cells and breast cancer cell lines with and without EMT features to characterize the mechanism of selectivity towards EMT(+) cells by OpA and to identify novel targets for the treatment of EMT-enriched breast cancer. Proteins interacting with OpA in EMT(+) cells were identified through proteomic studies. We utilized trans-mitochondrial cybrids to determine that mitochondria mediate sensitivity to OpA. Furthermore, we report effects on glycolysis, oxidative metabolism, and disruption of metabolite abundance in the TCA cycle. Alterations to mitochondrial iron concentrations and glutathione production, mediated partly by OpA engagement with the metabolic proteins CISD3 and SLC25A40, were also detected in EMT(+) cells. Antioxidant mechanisms are activated by OpA in EMT(+) cells via the NRF2-ARE pathway, verified by decreased cytotoxicity in EMT(+) cells pretreated with the NRF2 activator CDDO. Collectively, we conclude that OpA selectivity toward EMT is mediated by the mitochondria, and at sub-cytotoxic levels, generates a metabolic shift leading to cell death countered by antioxidant mechanisms.

Similar Papers

biorxiv
Tue Apr 15 2025
Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells.
Patients with Acute Myeloid Leukemia (AML) subtypes, acute erythroleukemia and acute megakaryocytic leukemia (M6 and M7 AMLs, respectively) have a median survival of only a few months with no targeted effective treatment. Our gene expression analysis using the Cancer Cell Line Encyclopedia and CRISPR screen from DepMap showed that M6/M7 AMLs have high levels of the transcription factor GATA1 and d...
Raza, Y.
•
Elmasry, M.
•
Yu, G.
•
Chiappone, S. B.
...•
Luberto, C.
biorxiv
Tue Apr 15 2025
The carnosinase dipeptidase CNDP1 is a novel metabolic vulnerability in brain metastasis
Brain metastatic cells undergo metabolic adaptations, such as increased reliance on oxidative phosphorylation. Integrating proteomic and transcriptomic profiling of patient samples revealed a consistent upregulation of the carnosine dipeptidase-1 (CNDP1) in brain versus extracranial metastases. Carnosine is an abundant metabolite in brain and muscle, known to exert anti-proliferative effects on ca...
Gomez-Munoz, M. A.
•
Karz, A.
•
Navarro, M.
•
Osorio-Vasquez, V. M.
...•
Hernando, E.
biorxiv
Tue Apr 15 2025
Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models
Background Diffuse midline glioma (DMG) is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. Since MAPK pathway activation is upstream of cell proliferation, we hypothesized that MEK inhibitors may increase the anti-tumor effects of CDK4/6 inhibitors. Here, we evaluated the efficacy...
Tomita, Y.
•
Link, G.
•
Ge, Y.
•
Gold, E. R. H.
...•
Becher, O. J.
biorxiv
Tue Apr 15 2025
Splice-switching ASOs targeting an Alu-derived exon in the AURKA 5'UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, driven by oncogenic KRAS mutations and dysregulated oncogenes, such as SRSF1, MYC, and AURKA. Although KRAS-targeted therapies are in development, resistance mechanisms underscore the need to identify alternative vulnerabilities. Here, we uncover an SRSF1-AURKA-MYC oncogenic circuit, wherein SRSF1 regulates AURKA 5\'UTR al...
Kral, A. J.
•
Jia, L.
•
Sim, G.
•
Wan, L.
•
Krainer, A. R.
biorxiv
Tue Apr 15 2025
A Dual-Action Liposome-Peptide Formulation Synergistically Counteracts A Gain-of-Function p53 Mutant
Objective. Inactivation of p53 tumor suppressor functions, often through missense mutations, is essential for carcinogenesis. A sub-class of such p53 missense mutations gains new functions, including drug resistance and enhanced proliferation, in addition to its loss of function. Among the most frequent gain-of-function p53 mutants, R273H occurs in tumors of many tissue origins and imparts aggress...
Ghosh Chaudhary, S.
•
Bhowmick, S.
•
Bhattacharya, S.
•
Roy, S.
•
Ali, N.
biorxiv
Tue Apr 15 2025
The E3 ligase HECTD4 regulates COX-2 dependent tumor progression and metastasis
E3 ubiquitin ligases mediating turnover of proteins engaged in cancer progression point to key regulatory nodes. To uncover modifiers of metastatic competency, we conducted an in vivo genome-wide CRISPR-inactivation screen using cultured breast circulating tumor cells, following intravascular seeding and lung colonization. We identified HECTD4, a previously uncharacterized gene encoding a conserve...
Vuille, J. A.
•
Tanriover, C.
•
Micalizzi, D. S.
•
Ebright, R. Y.
...•
Haber, D. A.
biorxiv
Tue Apr 15 2025
Quantifying replication stress in cancer without proliferation confounding
Replication stress (RS) is a major driver of genomic instability and cancer development, caused by impaired DNA replication that can lead to chromosomal instability (CIN). Although RS is mechanistically linked to CIN, its relationship with cellular proliferation is complex. Depending on the context, RS can either promote or suppress cell growth. Existing RS gene expression signatures overlook this...
Jungk, P.
•
Kschischo, M.
biorxiv
Tue Apr 15 2025
Proteomic Remodeling During Tumor Cell-Induced Platelet Aggregation Unveils Metastatic Drivers in Colorectal Cancer
Background: Colorectal cancer (CRC) is frequently associated with metastasis, resulting in high mortality rates. Platelets are known to play a crucial role in the metastatic cascade influencing tumor microenvironment remodeling, promoting cell transformation, facilitating metastatic niche formation, and shielding circulating tumor cells from immune surveillance. However, platelet proteomic alterat...
Sauer, T.
•
Gruner, C.
•
Kern, K.
•
Rackisch, A.
...•
Gemoll, T.
biorxiv
Tue Apr 15 2025
Tumoral CD24 tunes platelets binding and pro-metastatic functions
One of the earliest steps of breast cancer metastasis occurs when tumor cells (TCs) disseminate through the bloodstream. There, they interact with several blood components. Among them, platelet favor TC survival and metastatic spread. While the binding of platelet to TC is highly variable, its molecular controls and downstream consequences remain unidentified. Here, we first document that high CD2...
Mittelheisser, V.
•
Liboni, C.
•
Mouriaux, C.
•
Trivigno, S. M. G.
...•
GOETZ, J. G.
biorxiv
Tue Apr 15 2025
Brief Pulses of High-Level Fluid Shear Stress Enhance Metastatic Potential and Rapidly Alter the Metabolism of Cancer Cells.
Circulating tumor cells (CTCs) face challenges to their survival including mechanical and oxidative stresses. Recently, we identified a mechano-adaptive response to transient fluid shear stress (FSS) exposure that enables cancer cells to survive mechanical destruction in the circulation and found that it involves an increase in the activation of RhoA-actomyosin signaling [1]. Because RhoA is likel...
Pope, A. N.
•
Moose, D. L.
•
Hudson, G. O.
•
Weresh, H. R.
...•
Henry, M. D.